SLP News and Press, Simulations Plus Inc. From 06/20/23

Acquisition increases breadth and depth of QSP expertise and range of therapeutic applications Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today ann...

Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the release of a new integrated pulmonary software and services package. This targeted package will support pharmaceutical companies ...

2023-05-02 12:38:45 ET Summary Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growth begin to quickly slow. Retention data sugges...

Provides FDA with software tools to investigate drug-induced liver injury in clinical trials Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that the U.S. FDA has rene...

2023-04-05 20:09:08 ET Simulations Plus, Inc. (SLP) Q2 2023 Earnings Conference Call March 05, 2023 05:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call P...

2023-04-05 16:10:34 ET Simulations Plus press release ( NASDAQ: SLP ): Q2 GAAP EPS of $0.20 beats by $0.02 . Revenue of $15.75M (+6.4% Y/Y) misses by $0.38M . Software revenue increased 7% to $10.5 million, representing 67% of total revenue; Services revenu...

Total revenue of $15.8 million; Diluted Earnings Per Share (EPS) of $0.20; Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67 Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and s...

More than 150 people from around the world gathered virtually this past February for a panel discussion about how to move the needle on gender equity for women in science. Hosted by Simulations Plus, Inc. (Nasdaq: SLP) as part of their third annual Model-Informed Drug Development (MIDD+...

Drug discovery services partnership with Sino-American Cancer Foundation focuses on the development of actionable hits against the MTHFD2 target Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and ...

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wedn...